Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04959253
PHASE2

Psilocybin in Depression Resistant to Standard Treatments

Sponsor: King's College London

View on ClinicalTrials.gov

Summary

A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive disorder. The primary objective is to evaluate feasibility by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (MADRS).

Official title: A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study

Key Details

Gender

All

Age Range

25 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2021-06-21

Completion Date

2024-12-18

Last Updated

2026-08-28

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

Psilocybin assisted therapy

A package of psychological therapy and a single dosing session of psilocybin.

COMBINATION_PRODUCT

Placebo assisted therapy

A package of psychological therapy and a single dosing session of placebo.

Locations (1)

Clinical Research Facility, King's College Hospital

London, London, United Kingdom